Immunogenicity of Measles and Rubella Vaccines in Oman: A Prospective Clinical Trial

Vaccination News Home Page                                            subscribe Vaccination NewsLetter

http://www.journals.uchicago.edu/JID/journal/issues/v187nS1/020454/brief/020454.abstract.html

The Journal of Infectious Diseases    2003;187:S177-S185
© World Health Organization 2003. All rights reserved. The World Health Organization has granted the Publisher permission for the reproduction of this article.
0022-1899/2003/18710S-0028

 

Go to full text | Return to Issue Table of Contents

SUPPLEMENT ARTICLE

Immunogenicity of Measles and Rubella Vaccines in Oman: A Prospective Clinical Trial

Kathryn A. Kohler,1 Ali Jaffer M. Suleiman,3 Susan E. Robertson,5 Pradeep Malankar,3 Saleh Al-Khusaiby,4 Rita F. Helfand,2 David Brown,6 William J. Bellini,2 and Roland W. Sutter1,a

1Global Immunization Division, National Immunization Program, and 2Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; 3Ministry of Health and 4Royal Hospital, Muscat, Oman; 5Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland; 6Enteric, Respiratory and Neurological Virus Laboratory, Central Public Health Laboratory, London, United Kingdom

 

A prospective immunogenicity trial of measles and rubella vaccines was conducted in Oman. Children received measles vaccine at age 9 months and measles-rubella vaccine at age 15 months. Serum specimens were tested for measles-specific IgG and rubella-specific IgG. Of 1025 eligible infants, 881 (86.0%) returned for all five visits and had adequate serum samples for testing. Seroconversion to measles after vaccination at 9 months was 98.1%. At 15 months, 47 (5.3%) of the 881 children were seronegative for measles; of these, 44 (93.6%) seroconverted. At 16 months, 99% of the children seronegative at age 9 months seroconverted after receiving two doses of measles vaccine. At age 15 months, 684 (77.6%) children were seronegative for rubella. Of these, 676 (98.8%) seroconverted by age 16 months. One dose of measles vaccine at age 9 months was highly immunogenic. One dose of measles-rubella vaccine at age 15 months closed the remaining measles immunogenicity gap and resulted in a high rate of rubella seroconversion.

 


     The study protocols for phase I and phase II of this clinical trial were approved by the National Maternal Child Health Committee, Ministry of Health, Oman; the Institutional Review Board, Centers for Disease Control and Prevention, Atlanta; and the Secretariat Committee for Research Involving Human Subjects, World Health Organization, Geneva. Witnessed oral parental consent was obtained for each study subject; consent was obtained separately for phase I and phase II of the study.
     Financial support: Department of Vaccines and Biologicals, World Health Organization (Geneva). SmithKline Beecham (Rixensart, Belgium) provided the study vaccines free of charge.
     a Present affiliation: Vaccine Assessment and Monitoring, Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Go to full text | Return to Issue Table of Contents

 

Vaccination News Home Page

 

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.